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Abstract
Background: The risk of death due to COVID-19 among hospitalized patients is known to be 
higher in older adults and those with underlying health conditions. Understanding the percent-
age of patients who are at increased risk of death due COVID-19 and how this varies between 
age groups will inform the healthcare community how to evaluate the risk of COVID-19, and 
better design healthcare and economic policies.  
Methods: We conducted a literature search for studies published between December 2019 
until May 16, 2020 in PubMed, Embase, and Cochrane (CENTRAL). Descriptive statistics were 
performed. 
Results: We reviewed 14 studies of which 13 were retrospective and one was prospective. 
Eleven studies were conducted in Wuhan, China. A grand total of 11,938 COVID-19 confirmed 
patients were reviewed. Among these patients, 7637 (64%) were males. Our review report-
ed hypertension (41%), diabetes (21%), cardiac diseases (14%), COPD (8%), chronic kidney 
disease (4%) and cerebrovascular disease (10%) as the most common underlying diseases 
among patients who died during hospitalization due to COVID-19. The total number of patients 
died in the hospital was 1744 (15%). Among patients who died in the hospital, 1% patients were 
30-39 years, 16% patients were 40-59 years and 83% patients were more than 60 years of age.
Conclusions: Older patients with underlying diseases appear to be at higher risk of mortali-
ty from COVID-19. Comorbidities are significant predictors of mortality in COVID-19 patients. 
There is an urgent need to know the epidemiology of the novel virus and characterize its po-
tential impact.
Introduction
The first case of Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-
CoV-2) was reported in Wuhan, China in December 2019. The World Health Organiza-
tion (WHO) recognized this virus as a global pandemic on March 11, 2020. [1] It is caused 
by a positive–sense RNA virus. It is a highly infectious virus, and has been reported to 
have 1-5% mortality rate or more. [2] Individuals from all age groups are susceptible to 
SARS-CoV-2 infection. Coronavirus disease-2019 (COVID-19) is the syndrome caused 
by this virus, and is associated with higher mortality than influenza. [3] It is difficult to 
estimate the COVID-19 global mortality, given the high variability in testing and man-
agement strategies adopted in different countries. The COVID-19 mortality rate is cal-
culated as the number of deaths due to COVID-19 divided by the total COVID-19 cases. 
The total cases available to count are those who are evaluated either test positive or are 
clinically diagnosed despite a negative test. However, it’s a challenge to capture the total 
cases of COVID-19, because it is difficult to trace asymptomatic cases, especially with 
limited resources and inadequate testing in some parts of the world. [4] The mortality 
rate due to COVID-19 varies among different age groups in different countries. [5] 
The age-related mortality risk cannot be estimated accurately with the current limited 
information regarding prevalence, mortality and overall epidemiology of COVID-19. [6] 
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There is an urgent need to know the epidemiology of the novel virus and characterize its potential impact. This infor-
mation is essential for the healthcare community to evaluate the risk of COVID-19 in patients, and design health and 
economic policies. We will describe the mortality in COVID-19 patients as they relate to different age groups and co-
morbidities in this review.
Methods
Data sources and search strategy
We conducted a literature search for articles published (including ahead of print) until May 16, 2020 in PubMed, Em-
base, and Cochrane (CENTRAL). The search was conducted on May 14, 2020. Articles reporting mortality rates from 
COVID-19 were included in the review. We searched articles by using keywords with combinations of “COVID-19” 
AND “mortality”, “coronavirus” AND “mortality”, “SARS-CoV-2” AND “mortality”. Studies that did not report data 
about mortality or death rate due to COVID-19 were excluded from this review. Studies conducted in hospital, out-
patient, or intensive care unit (ICU) were included. Duplicate publications, reviews, editorials, case reports, letters, 
surveillance, non-English and articles predicting mortality were not included. A flow diagram of literature search is 
shown in Figure 1. 
Figure 1. Flow Diagram
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Data extraction 
Two authors independently reviewed each article by reviewing title and abstract using Rayyan. [7] The full text of 
included articles was reviewed. Any conflict between two authors for selecting studies for this review were resolved 
through discussion and review by a third author. The following variables were extracted: author, study type, date, age, 
gender, total number of participants, comorbidities, mortality rate. 
We identified a total of 704 articles. After removing duplicates, the authors checked the title, abstract and full articles of 
included studies. The primary outcome of our analysis was in-hospital mortality.  Studies that reported mortality rate 
not stratified by comorbidities or by age group were excluded. Out of these, we found fourteen studies where mortality 
rate was stratified by comorbidities or by age groups. These studies were included into this review. 
Table 1. Studies characteristics included in analysis.
Study Study Design City, Country Hospital Setting Total patients
Males,
N (%)
Median 
age[years] 
(IQR)
1. Fei Zhou et al [8] Retrospective, multicenter cohort study Wuhan, China
Inpatients 191 119(62) 56·0 (46·0–67·0)
2. Xiaobo Yang et al [9] Retrospective observational Wuhan, China
Intensive care 
unit 52 35(67) 59·7 (13·3)
3. Mingli Yuan et al [10] Retrospective Wuhan, China Inpatient 27 12(45) 60 ( 47–69)
4.
Giacomo Grasselli et 
al [11] Retrospective case series 
72 hospitals, 
Lombard, Italy
Intensive care 
unit
1591 1304 (82) 63 (56-70) 
5. Jianlei Cao et al [12] Retrospective cohort Wuhan, China Inpatient 102 54(52) 54 (37-67)
6. Tao Chen et al [13] Retrospective case series Wuhan, China Inpatients 274 171 (62) 62.0 (44.0-70.0)
7. Xun Li et al [14] Retrospective Wuhan, China Inpatients 25 10(40) 71.48* ± 12.42
8. Nikpouraghdam M et al [15] Retrospective Tehran, Iran Inpatients 2968 1958(66) 56(46-65) 
9. Safiya Richardson [16] Retrospective
12 hospitals, New 
York, USA Inpatients 5700 3437(60) 63( 52-75)
10. Bicheng Zhang [17] Retrospective Wuhan, China Inpatients 82 54 (66) 72.5 (65.0-80.0)
11. Lin Fu et al [18] Retrospective Wuhan, China Inpatients 200 99 (49) NA
12.
TieLong Chen et 
al [19] Retrospective Wuhan, China Inpatients 203 108 (53)  54 (41–68)
13. Yang Wang [20] Retrospective Wuhan, China Intensive care unit 344 179 (52) 64 (52-72)
14. Rong-Hui Du [21] Prospective Wuhan, China Inpatients 179 97 (54) 57.6*±13.7
Total 11938 7637
*= Mean age
NA=Not available
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Results
We reviewed 14 studies, which included 13 retrospective and one prospective study. Eleven studies were conducted in 
Wuhan, China. A total of 11,938 confirmed COVID-19 patients were included in the review. Among these total patients, 
7637 (64%) were males. All patients included in the review were hospitalized patients with confirmed diagnosis of 
COVID-19. The diagnostic test used for confirmation was reverse transcriptase-polymerase chain reaction assay of 
nasal or pharyngeal swabs. 
Our review reported hypertension, diabetes, cardiac diseases as the most common underlying diseases among patients 
who died during hospitalization due to COVID-19.  Chronic cardiac diseases included chronic heart disease and coro-
nary heart disease. Social history of current smoking was present in 13% of patients.  
The total number of patients who died in the hospital was 1744 (15%). Among the patients who died in the hospital, 1% 
were 30-39 years old, 16% were 40-59 years and 82% were more than 60 years of age.
Discussion
The analysis from this manuscript demonstrates that age and presence of underlying diseases correlate with risk of 
death from COVID-19. The severity of disease presentation increases with age. The most common co-morbidity was 
hypertension among hospitalized patients who died from SARS-CoV2. Patients with cardiovascular disease and dia-
betes were also at high risk of death from this pathogen.  Interestingly, our data also demonstrates that male sex was 
associated with higher mortality. 
Multiple studies have corroborated our findings that elderly patients are at a higher risk of mortality from COVID-19. 
[22] Approximately 80% of deaths occurred among adults over the age of 60-years. One mechanism of this phenom-
enon is that older age can lead to defects in T cell and B cell function, causing an excess inflammatory response con-
tributing to worse outcomes. [8] Furthermore, several studies have demonstrated that hypertension and cardiovas-
cular disease portends poor prognosis. [23] Patients with a history of hypertension have 2.5-fold higher risk of fatal 
COVID-19, especially older age groups when compared to patients without hypertension. [24] Another study demon-
strates that the presence of cardiovascular risk factors does not increase the likelihood of developing the infection but 
are associated with an increased COVID-19-related mortality. [2,23] One potential mechanism of cardiovascular events 
from SARS-CoV-2 is from the release of cytokines and chemokines that can precipitate vascular inflammation, plaque 
instability and myocardial inflammation. [25] A recent study reported myocardial injury in 20% of patients confirmed 
with COVID-19, and who were associated with a higher mortality rate. [26]
Our data suggest that diabetes is a prominent co-morbid condition that increases the risk of COVID-19 related morbid-
ity. Diabetic patients are more likely to be older than non-diabetes patients, whereas older age is also associated with 
higher mortality due to COVID-19. [27] Previous studies have also reported an association of diabetes with poor prog-
nosis in other viral infections like seasonal influenza, H1N1 influenza, and Severe Acute Respiratory Syndrome (SARS). 
[28,29,30] There is scarce data about glucose metabolism and the development of acute complications of diabetes like 
ketoacidosis in patients with COVID-19. Infection due to SARS-CoV-2 in patients with diabetes possibly triggers higher 
stress conditions by releasing hyperglycemic hormones like glucocorticoids and catecholamines that can lead to in-
creased blood glucose levels. [31] In diabetic patients, COVID-19 can progress rapidly to acute respiratory distress syn-
drome, septic shock and organ failure. [31] Diabetes causes impaired neutrophil chemotaxis and phagocytosis which 
predisposes diabetic patients to infections in general. [32]
Our study also demonstrates that male sex was associated with higher mortality. A recent case study conducted at a 
hospital in Wuhan, China also showed a higher percentage of males died compared to females. This study showed that 
men were approximately two times more likely than females to die from COVID-19, and that sex is an independent risk 
Table 2. Mortality reported in studies stratified by comorbidities. 
Risk Factor Mortality (%)
Hypertension 41
Diabetes 21
Chronic cardiac diseases 14
Smoking 13
Cerebrovascular disease 10
Chronic obstructive pulmonary disease (COPD) 8
Chronic kidney disease 4
Table 3. Mortality reported in studies stratified by age.
Age group Mortality (%)
0-19 years 0%
20-29 years 0.3%
30-39 years 1%
40-59 years 16%
≥60 years 82%
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factor for severity and mortality in COVID-19 patients. [22]
Our review has few limitations. As most of the studies are from China and may present a location bias in the results. 
Furthermore, not all case studies reported co-morbid conditions related to COVID-19 mortality. Our study only utilized 
descriptive statistics and did not calculate if co-morbid conditions or age were independent predictors of outcomes. 
Because of the descriptive nature of these data, attack rates among patients with and without underlying health condi-
tions could not be compared, and thus the risk difference of severe disease with COVID-19 between these groups could 
not be estimated. However, this is one of the few studies to review the risk of age and co-morbidities from COVID-19. 
Future prospective studies will be essential to corroborate these findings. 
In conclusion, older patients with underlying disease appear to be at a higher risk of mortality from COVID-19. Comor-
bidities are significant predictors of mortality in COVID-19 patients. More studies are needed to understand underlying 
pathophysiological mechanisms of risk-factors and age in association with COVID-19.
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